Literature DB >> 12487620

Responsible prescribing of opioids for the management of chronic pain.

Bruce Nicholson1.   

Abstract

The management of patients with chronic pain is a common clinical challenge. Indeed, chronic pain is often inadequately controlled in patients with cancer and in those with non-cancer chronic pain. Because of the complex nature of chronic pain, successful long-term treatment is more difficult than for acute pain. Most often acute pain is nociceptive, whereas chronic pain can be nociceptive (i.e., in response to noxious stimuli), neuropathic (i.e., initiated by a primary lesion or dysfunction in the nervous system) or mixed in origin. Opioids are the current standard of care for the treatment of moderate or severe nociceptive pain. Opioids mediate their actions by binding and activating receptors both in the peripheral nervous system and those that are found in inhibitory pain circuits that descend from the midbrain to the spinal cord dorsal horn. Opioid agonists exert a number of physiological responses including analgesia, which increases with increasing doses. The use of opioids to manage pain in patients with cancer is well accepted. The WHO step-wise algorithm for analgesic therapy based on pain severity reserves the use of opioid therapy for moderate and severe pain. The WHO algorithm has proven to be highly effective for the management of cancer pain. However, the use of opioids to treat patients with chronic non-cancer pain is controversial because of concerns about efficacy and safety, and the possibility of addiction or abuse. The results of clinical surveys and retrospective case series involving patients with non-cancer chronic pain have been inconsistent in regard to resolving these controversial issues. The oral route of drug administration is most appropriate for patients receiving opioids; although rectal, transdermal and parenteral routes of administration are used in specific situations. For continuous chronic pain, opioids should be administered around-the-clock and several long-acting formulations are available that require administration only once or twice daily. Opioid doses should be titrated according to agent-specific schedules to maximise pain relief and maintain tolerability. Adverse effects include constipation, nausea and vomiting, sedation, cognitive impairment and respiratory depression. Tolerance to the analgesic and adverse effects as well as physical dependence, which causes withdrawal symptoms upon discontinuance, may occur with opioid use. Estimates of addiction rates among patients with chronic non-cancer pain range from 3.2 to 18.9%. Successful pain treatment and symptom management is an attainable goal for the majority of patients with chronic pain. Further controlled clinical trials are needed to define the role of opioid therapy in chronic non-cancer pain, and to establish criteria for patient selection and specific treatment algorithms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12487620     DOI: 10.2165/00003495-200363010-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  47 in total

1.  Chronic pain: challenges in the assessment and management of cancer pain.

Authors:  R Payne
Journal:  J Pain Symptom Manage       Date:  2000-01       Impact factor: 3.612

Review 2.  Cancer pain relief and palliative care. Report of a WHO Expert Committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1990

3.  Cancer pain management according to WHO analgesic guidelines.

Authors:  S A Schug; D Zech; U Dörr
Journal:  J Pain Symptom Manage       Date:  1990-02       Impact factor: 3.612

4.  Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.

Authors:  S Ahmedzai; D Brooks
Journal:  J Pain Symptom Manage       Date:  1997-05       Impact factor: 3.612

5.  Practice guidelines for chronic pain management. A report by the American Society of Anesthesiologists Task Force on Pain Management, Chronic Pain Section.

Authors: 
Journal:  Anesthesiology       Date:  1997-04       Impact factor: 7.892

6.  Driving ability in cancer patients receiving long-term morphine analgesia.

Authors:  A Vainio; J Ollila; E Matikainen; P Rosenberg; E Kalso
Journal:  Lancet       Date:  1995-09-09       Impact factor: 79.321

7.  Effects of opioids on driving ability.

Authors:  T Galski; J B Williams; H T Ehle
Journal:  J Pain Symptom Manage       Date:  2000-03       Impact factor: 3.612

8.  Pain and its treatment in outpatients with metastatic cancer.

Authors:  C S Cleeland; R Gonin; A K Hatfield; J H Edmonson; R H Blum; J A Stewart; K J Pandya
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

9.  Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia.

Authors:  C P Watson; N Babul
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

10.  Spinal cord mechanisms of opioid tolerance and dependence: Fos-like immunoreactivity increases in subpopulations of spinal cord neurons during withdrawal [corrected].

Authors:  D S Rohde; D J Detweiler; A I Basbaum
Journal:  Neuroscience       Date:  1996-05       Impact factor: 3.590

View more
  37 in total

1.  Trends in consumption of opioid analgesics in Slovak Republic during 1998-2002.

Authors:  R Hudec; J Tisonová; L Bozeková; V Foltán
Journal:  Eur J Clin Pharmacol       Date:  2004-07-01       Impact factor: 2.953

Review 2.  Tapentadol extended release: in adults with chronic pain.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2012-02-12       Impact factor: 9.546

3.  Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone.

Authors:  Irfan A Dhalla; Muhammad M Mamdani; Marco L A Sivilotti; Alex Kopp; Omar Qureshi; David N Juurlink
Journal:  CMAJ       Date:  2009-12-07       Impact factor: 8.262

Review 4.  Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?

Authors:  Bernard Bannwarth
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

5.  Outcomes associated with a cognitive-behavioral chronic pain management program implemented in three public HIV primary care clinics.

Authors:  Jodie A Trafton; John T Sorrell; Mark Holodniy; Heather Pierson; Percy Link; Ann Combs; Dennis Israelski
Journal:  J Behav Health Serv Res       Date:  2012-04       Impact factor: 1.505

6.  Sleep and GABA levels in the oral part of rat pontine reticular formation are decreased by local and systemic administration of morphine.

Authors:  C J Watson; R Lydic; H A Baghdoyan
Journal:  Neuroscience       Date:  2006-10-19       Impact factor: 3.590

7.  Predicting response to cognitive-behavioral therapy in a sample of HIV-positive patients with chronic pain.

Authors:  Michael A Cucciare; John T Sorrell; Jodie A Trafton
Journal:  J Behav Med       Date:  2009-02-21

8.  Behavioral, medical imaging and histopathological features of a new rat model of bone cancer pain.

Authors:  Louis Doré-Savard; Valérie Otis; Karine Belleville; Myriam Lemire; Mélanie Archambault; Luc Tremblay; Jean-François Beaudoin; Nicolas Beaudet; Roger Lecomte; Martin Lepage; Louis Gendron; Philippe Sarret
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

9.  Behavioral and neurochemical changes induced by oxycodone differ between adolescent and adult mice.

Authors:  Yong Zhang; Roberto Picetti; Eduardo R Butelman; Stefan D Schlussman; Ann Ho; Mary Jeanne Kreek
Journal:  Neuropsychopharmacology       Date:  2008-09-10       Impact factor: 7.853

Review 10.  Medical and genetic differences in the adverse impact of sleep loss on performance: ethical considerations for the medical profession.

Authors:  Charles A Czeisler
Journal:  Trans Am Clin Climatol Assoc       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.